ESSA Pharma Inc.
EPIX · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $104 | $34 | $57 | $138 |
| Short-Term Investments | $23 | $114 | $0 | $57 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $111 | $0 |
| Other Curr. Assets | $1 | $1 | $2 | $2 |
| Total Curr. Assets | $128 | $149 | $170 | $198 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $0 | $0 | $1 |
| Other Assets | $0 | $0 | -$0 | $0 |
| Total Assets | $128 | $149 | $170 | $198 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $1 | $1 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | -$35 | -$37 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1 | $1 | $36 | $39 |
| Total Curr. Liab. | $3 | $3 | $2 | $4 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $4 | $3 | $2 | $4 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $280 | $278 | $278 | $277 |
| Retained Earnings | -$208 | -$179 | -$153 | -$118 |
| AOCI | -$2 | -$2 | -$2 | -$2 |
| Other Equity | $55 | $49 | $44 | $36 |
| Total Equity | $125 | $146 | $167 | $194 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $128 | $149 | $170 | $198 |
| Net Debt | -$103 | -$34 | -$57 | -$137 |